Social Reintegration of Hodgkin's Survivors Impeded by Fatigue

This article originally appeared here.
Share this content:
Social Reintegration of Hodgkin's Survivors Impeded by Fatigue
Social Reintegration of Hodgkin's Survivors Impeded by Fatigue

WEDNESDAY, Oct. 12, 2016 (HealthDay News) -- Severe fatigue (sFA) can impede social reintegration in Hodgkin's lymphoma (HL) survivors, according to a study published online Oct. 3 in the Journal of Clinical Oncology.

Karolin Behringer, M.D., from the University Hospital of Cologne in Germany, and colleagues examined data on health-related quality of life for 4,529 patients enrolled in the German Hodgkin Study Group's fifth generation of clinical trials in HL. sFA was assessed before and up to nine years after therapy.

The researchers found that 37 percent of patients reported sFA at baseline; during follow-up, sFA varied from 20 to 24 percent. There was a correlation for baseline sFA with significantly impaired progression-free survival, and a trend toward impaired overall survival, which could be overcome for patients receiving highly effective HL therapies. In survivors there was a significant negative association for sFA and employment: five years after therapy, 51 percent of female survivors and 63 percent of males with sFA were working or in professional education, compared with 78 and 90 percent of those without sFA (adjusted P < 0.001). There was a correlation for sFA with financial problems and the number of visits to a general practitioner and medical specialists.

"This observation underscores the need to address fatigue as a significant diagnosis when treating patients with and survivors of cancer," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »